Advanced Life Sciences Holdings, Inc. - Product Pipeline Review - Q4 2010

Advanced Life Sciences Holdings, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Advanced Cancer Therapeutics - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Advanced Cancer Therapeutics - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Advanced Cancer Therapeutics human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Advanced Cancer Therapeutics with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Advanced Cancer Therapeutics’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Advanced Cancer Therapeutics’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Advanced Cancer Therapeutics in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Advanced Cancer Therapeutics’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Advanced Cancer Therapeutics.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Advanced Cancer Therapeutics and identify potential opportunities in those areas. SHOW LESS READ MORE >

List of Tables
List of Figures
Advanced Life Sciences Holdings, Inc. Snapshot
Advanced Life Sciences Holdings, Inc. Overview
Key Information
Key Facts
Advanced Life Sciences Holdings, Inc. – Research and Development Overview
Key Therapeutic Areas
Advanced Life Sciences Holdings, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Advanced Life Sciences Holdings, Inc. – Pipeline Products Glance
Advanced Life Sciences Holdings, Inc. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Advanced Life Sciences Holdings, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Advanced Life Sciences Holdings, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Advanced Life Sciences Holdings, Inc. – Drug Profiles
Restanza
Product Description
Mechanism of Action
R&D Progress
ALS-357
Product Description
Mechanism of Action
R&D Progress
ALS-886
Product Description
Mechanism of Action
R&D Progress
Restanza
Product Description
Mechanism of Action
R&D Progress
Advanced Life Sciences Holdings, Inc. – Pipeline Analysis
Advanced Life Sciences Holdings, Inc. – Pipeline Products by Therapeutic Class
Advanced Life Sciences Holdings, Inc. Pipeline Products By Target
Advanced Life Sciences Holdings, Inc. – Pipeline Products by Route of Administration
Advanced Life Sciences Holdings, Inc. – Pipeline Products by Molecule Type
Advanced Life Sciences Holdings, Inc. – Recent Pipeline Updates
Advanced Life Sciences Holdings, Inc. – Company Statement
Advanced Life Sciences Holdings, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Nov 18, 2010: Advanced Life Sciences Applies For FDA Orphan Drug Designation For ALS-886 To Treat Acute Lung Injury
Nov 09, 2010: Advanced Life Sciences Submits Full Proposal To NIAID For Development Of Intravenous Formulation Of Restanza As Biodefense Countermeasure
Nov 09, 2010: Advanced Life Sciences Submits Full Proposal To NIAID For Development Of Intravenous Formulation Of Restanza As Biodefense Countermeasure
Nov 09, 2010: Advanced Life Sciences Submits Full Proposal To NIAID For Development Of Intravenous Formulation Of Restanza As Biodefense Countermeasure
Nov 09, 2010: Advanced Life Sciences Submits Full Proposal To NIAID For Development Of Intravenous Formulation Of Restanza As Biodefense Countermeasure
Nov 02, 2010: Advanced Life Sciences Announces US Army Collaboration To Research And Develop Restanza For Treatment Of Malaria
Aug 24, 2010: Advanced Life Sciences Sees Funding Opportunity For Restanza In New HHS Medical Countermeasure Report
Aug 10, 2010: Advanced Life Sciences Reports SPA Agreement With FDA For Restanza For Treatment Of Pneumonia
Jul 28, 2010: Advanced Life Sciences Applies For FDA Fast-Track Designation For Restanza For Treatment Of CABP
Jul 08, 2010: Advanced Life Sciences Reports Positive Preclinical Data Supporting Restanza Intravenous Formulation For Hospital Use
Financial Deals Landscape
Advanced Life Sciences Holdings, Inc., Deals Volume Summary, 2004 to YTD 2010
Advanced Life Sciences Holdings, Inc., Deals Summary By Region, 2004 to YTD 2010
Advanced Life Sciences Holdings, Inc., Deals Summary, 2004 to YTD 2010
Advanced Life Sciences Holdings, Inc. Detailed Deal Summary
Equity Offering
Advanced Life Sciences Holdings Completes Private Placement Of $3.9 Million
Advanced Life Sciences Holdings Completes Private Placement Of $1.71 Million
Advanced Life Sciences Completes Private Placement Of $2 Million
Advanced Life Sciences Completes Private Placement Of $20 Million
Advanced Life Sciences Completes Private Placement Of $36 Million
Advanced Life Sciences Completes Initial Public Offering Of $32.5 Million
Advanced Life Sciences Enters Into An Agreement With Wyeth
Licensing Agreements
Abbott Laboratories Enters Into Licensing Agreement With Advanced Life Sciences Holdings
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer